Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.46
BCR's Cash to Debt is ranked lower than
71% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. BCR: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
BCR' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.81 Max: 4.9
Current: 0.46
0.06
4.9
Equity to Asset 0.28
BCR's Equity to Asset is ranked lower than
87% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. BCR: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
BCR' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.56 Max: 0.77
Current: 0.28
0.28
0.77
Interest Coverage 7.83
BCR's Interest Coverage is ranked lower than
68% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.78 vs. BCR: 7.83 )
Ranked among companies with meaningful Interest Coverage only.
BCR' s Interest Coverage Range Over the Past 10 Years
Min: 7.78  Med: 27.40 Max: 59.45
Current: 7.83
7.78
59.45
F-Score: 5
Z-Score: 3.60
M-Score: -3.09
WACC vs ROIC
5.93%
3.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.13
BCR's Operating margin (%) is ranked higher than
65% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. BCR: 10.13 )
Ranked among companies with meaningful Operating margin (%) only.
BCR' s Operating margin (%) Range Over the Past 10 Years
Min: 10.23  Med: 24.71 Max: 41.51
Current: 10.13
10.23
41.51
Net-margin (%) 3.22
BCR's Net-margin (%) is ranked higher than
52% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.86 vs. BCR: 3.22 )
Ranked among companies with meaningful Net-margin (%) only.
BCR' s Net-margin (%) Range Over the Past 10 Years
Min: 3.96  Med: 17.46 Max: 22.62
Current: 3.22
3.96
22.62
ROE (%) 7.01
BCR's ROE (%) is ranked higher than
55% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. BCR: 7.01 )
Ranked among companies with meaningful ROE (%) only.
BCR' s ROE (%) Range Over the Past 10 Years
Min: 8.19  Med: 21.92 Max: 34.37
Current: 7.01
8.19
34.37
ROA (%) 2.23
BCR's ROA (%) is ranked higher than
52% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. BCR: 2.23 )
Ranked among companies with meaningful ROA (%) only.
BCR' s ROA (%) Range Over the Past 10 Years
Min: 2.7  Med: 14.07 Max: 17.1
Current: 2.23
2.7
17.1
ROC (Joel Greenblatt) (%) 46.55
BCR's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.41 vs. BCR: 46.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BCR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 49.28  Med: 76.49 Max: 148.85
Current: 46.55
49.28
148.85
Revenue Growth (3Y)(%) 8.90
BCR's Revenue Growth (3Y)(%) is ranked higher than
70% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BCR: 8.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BCR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.7  Med: 10.40 Max: 13.4
Current: 8.9
-0.7
13.4
EBITDA Growth (3Y)(%) -10.20
BCR's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. BCR: -10.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BCR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.9  Med: 11.10 Max: 25.4
Current: -10.2
-18.9
25.4
EPS Growth (3Y)(%) -34.00
BCR's EPS Growth (3Y)(%) is ranked lower than
88% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. BCR: -34.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BCR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34  Med: 11.50 Max: 28.5
Current: -34
-34
28.5
» BCR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

BCR Guru Trades in Q2 2015

Ray Dalio 20,138 sh (New)
Paul Tudor Jones 208,490 sh (+37.80%)
Pioneer Investments 964,826 sh (+0.05%)
Vanguard Health Care Fund 912,700 sh (unchged)
John Hussman 10,000 sh (unchged)
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Steven Cohen 244,800 sh (-10.49%)
Jeremy Grantham 194,621 sh (-13.85%)
Jim Simons 957,500 sh (-13.96%)
Yacktman Fund 1,350,000 sh (-14.01%)
Donald Yacktman 2,773,248 sh (-16.64%)
Yacktman Focused Fund 950,000 sh (-22.13%)
» More
Q3 2015

BCR Guru Trades in Q3 2015

Joel Greenblatt 3,956 sh (New)
Tom Gayner 4,000 sh (New)
Ray Dalio 21,738 sh (+7.95%)
Pioneer Investments 973,664 sh (+0.92%)
John Hussman 10,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons 890,900 sh (-6.96%)
Vanguard Health Care Fund 784,800 sh (-14.01%)
Yacktman Fund 950,000 sh (-29.63%)
Jeremy Grantham 126,470 sh (-35.02%)
Donald Yacktman 1,464,225 sh (-47.20%)
Paul Tudor Jones 82,889 sh (-60.24%)
Yacktman Focused Fund 200,000 sh (-78.95%)
» More
Q4 2015

BCR Guru Trades in Q4 2015

Tom Gayner 9,000 sh (+125.00%)
Joel Greenblatt 7,682 sh (+94.19%)
Paul Tudor Jones 154,977 sh (+86.97%)
Jim Simons 1,098,500 sh (+23.30%)
John Hussman 10,000 sh (unchged)
Yacktman Fund 900,000 sh (-5.26%)
Donald Yacktman 1,283,759 sh (-12.33%)
Jeremy Grantham 104,075 sh (-17.71%)
Yacktman Focused Fund 140,000 sh (-30.00%)
Ray Dalio 10,786 sh (-50.38%)
Pioneer Investments 446,068 sh (-54.19%)
Vanguard Health Care Fund 226,841 sh (-71.10%)
» More
Q1 2016

BCR Guru Trades in Q1 2016

Joel Greenblatt 150,877 sh (+1864.03%)
Ray Dalio 23,315 sh (+116.16%)
Paul Tudor Jones 225,900 sh (+45.76%)
Jim Simons 1,355,300 sh (+23.38%)
Tom Gayner 9,000 sh (unchged)
Yacktman Fund 900,000 sh (unchged)
Yacktman Focused Fund 140,000 sh (unchged)
Vanguard Health Care Fund Sold Out
John Hussman Sold Out
Donald Yacktman 1,276,894 sh (-0.53%)
Jeremy Grantham 69,375 sh (-33.34%)
Pioneer Investments 289,215 sh (-35.16%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:TRUMY, OTCPK:CLPBY, NAS:XRAY, NAS:ILMN, OTCPK:OCPNY, NYSE:WAT, NYSE:MTD, NAS:HOLX, NYSE:BAX, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, OTCPK:ESLOY, NAS:SIRO, NYSE:STE, NYSE:WST, OTCPK:GNGBY, OTCPK:AHICF, NYSE:MR, NYSE:HRC » details
Traded in other countries:BR6.Germany,
CR Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, and extended care facilities.

C.R. Bard Inc was incorporated in New Jersey in 1923. The Company is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities The Company participates in the markets for vascular, urology, oncology and surgical specialty products. It reports its sales in four product group categories: vascular, urology, oncology and surgical specialties. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty, (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; peripheral vascular stents, covered stents and vascular grafts; vena cava filters; biopsy devices; and electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters. The Company's urology products include basic drainage products, continence products and urological specialty products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. The Company's soft tissue repair products consist of hernia repair grafts, including both synthetic and natural-tissue configurations, and hernia fixation devices. The Company competes in the therapeutic and diagnostic medical device markets around the world. Its products are distributed domestically directly to hospitals and other healthcare institutions as well as through numerous hospitals/surgical supply and other medical specialty distributors with whom the Company has distribution agreements. The Company is subject to governmental laws and regulations.

Guru Investment Theses on C.R. Bard Inc

Donald Yacktman Comments on C.R. Bard - Nov 05, 2015

C.R. Bard (NYSE:BCR) was a solid performer in the third quarter. As a result, we reduced the Fund’s position size in Bard.

From Donald Yacktman (Trades, Portfolio)'s third quarter 2015 commentary.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about C.R. Bard Inc

5 Companies Achieve 52-Week Highs C.R. Bard, Tim Hortons, Thermo Fisher, Fiserv, Molson Coors reach landmarks
According to GuruFocus list of 52-week highs, these guru stocks have reached their 52-week highs. Read more...
Dividends’ True Contribution to Total Return May Surprise You Academic research has given mixed conclusions
In recent years, dividends’ contribution to total return has been one of the most heavily-studied topics in the investment world. Several conclusions about the contribution that dividends make to total return have been claimed. However, these conclusions vary greatly. I have seen studies claiming that 90% of returns are attributed to dividends, several claiming 50% or more, and others arguing for a 30% contribution. Ironically, they all seem to be correct depending on the data-sets and/or timeframes being measured. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 162.91
BCR's P/E(ttm) is ranked lower than
96% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.83 vs. BCR: 162.91 )
Ranked among companies with meaningful P/E(ttm) only.
BCR' s P/E(ttm) Range Over the Past 10 Years
Min: 14.25  Med: 22.77 Max: 160.3
Current: 162.91
14.25
160.3
Forward P/E 22.68
BCR's Forward P/E is ranked lower than
58% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 22.68 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 162.91
BCR's PE(NRI) is ranked lower than
96% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.60 vs. BCR: 162.91 )
Ranked among companies with meaningful PE(NRI) only.
BCR' s PE(NRI) Range Over the Past 10 Years
Min: 14.25  Med: 22.71 Max: 160.3
Current: 162.91
14.25
160.3
P/B 11.61
BCR's P/B is ranked lower than
95% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. BCR: 11.61 )
Ranked among companies with meaningful P/B only.
BCR' s P/B Range Over the Past 10 Years
Min: 3.22  Med: 4.59 Max: 11.43
Current: 11.61
3.22
11.43
P/S 4.98
BCR's P/S is ranked lower than
72% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.58 vs. BCR: 4.98 )
Ranked among companies with meaningful P/S only.
BCR' s P/S Range Over the Past 10 Years
Min: 2.56  Med: 3.62 Max: 4.9
Current: 4.98
2.56
4.9
PFCF 26.23
BCR's PFCF is ranked higher than
50% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.65 vs. BCR: 26.23 )
Ranked among companies with meaningful PFCF only.
BCR' s PFCF Range Over the Past 10 Years
Min: 10.1  Med: 17.54 Max: 37.02
Current: 26.23
10.1
37.02
POCF 22.92
BCR's POCF is ranked lower than
73% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.71 vs. BCR: 22.92 )
Ranked among companies with meaningful POCF only.
BCR' s POCF Range Over the Past 10 Years
Min: 9.09  Med: 14.96 Max: 26.91
Current: 22.92
9.09
26.91
EV-to-EBIT 50.67
BCR's EV-to-EBIT is ranked lower than
84% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.19 vs. BCR: 50.67 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 14.80 Max: 51.1
Current: 50.67
8
51.1
EV-to-EBITDA 32.33
BCR's EV-to-EBITDA is ranked lower than
85% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.22 vs. BCR: 32.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 12.90 Max: 32.6
Current: 32.33
7.2
32.6
PEG 229.00
BCR's PEG is ranked lower than
100% of the 59 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.45 vs. BCR: 229.00 )
Ranked among companies with meaningful PEG only.
BCR' s PEG Range Over the Past 10 Years
Min: 0.94  Med: 1.51 Max: 40.69
Current: 229
0.94
40.69
Shiller P/E 48.15
BCR's Shiller P/E is ranked lower than
65% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.99 vs. BCR: 48.15 )
Ranked among companies with meaningful Shiller P/E only.
BCR' s Shiller P/E Range Over the Past 10 Years
Min: 23.41  Med: 30.48 Max: 47.22
Current: 48.15
23.41
47.22
Current Ratio 1.49
BCR's Current Ratio is ranked lower than
77% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. BCR: 1.49 )
Ranked among companies with meaningful Current Ratio only.
BCR' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.47 Max: 5.88
Current: 1.49
1.14
5.88
Quick Ratio 1.17
BCR's Quick Ratio is ranked lower than
69% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.71 vs. BCR: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.95 Max: 4.72
Current: 1.17
0.62
4.72
Days Inventory 111.19
BCR's Days Inventory is ranked higher than
59% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. BCR: 111.19 )
Ranked among companies with meaningful Days Inventory only.
BCR' s Days Inventory Range Over the Past 10 Years
Min: 92.97  Med: 104.83 Max: 110.79
Current: 111.19
92.97
110.79
Days Sales Outstanding 48.19
BCR's Days Sales Outstanding is ranked higher than
72% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.04 vs. BCR: 48.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.56  Med: 59.67 Max: 63.66
Current: 48.19
47.56
63.66
Days Payable 26.96
BCR's Days Payable is ranked lower than
86% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.12 vs. BCR: 26.96 )
Ranked among companies with meaningful Days Payable only.
BCR' s Days Payable Range Over the Past 10 Years
Min: 18.23  Med: 20.85 Max: 28.74
Current: 26.96
18.23
28.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.42
BCR's Dividend Yield is ranked lower than
86% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BCR: 0.42 )
Ranked among companies with meaningful Dividend Yield only.
BCR' s Dividend Yield Range Over the Past 10 Years
Min: 0.41  Med: 0.70 Max: 0.9
Current: 0.42
0.41
0.9
Dividend Payout 0.63
BCR's Dividend Payout is ranked lower than
76% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.38 vs. BCR: 0.63 )
Ranked among companies with meaningful Dividend Payout only.
BCR' s Dividend Payout Range Over the Past 10 Years
Min: 0.03  Med: 0.17 Max: 1.31
Current: 0.63
0.03
1.31
Dividend Growth (3y) 5.70
BCR's Dividend Growth (3y) is ranked lower than
73% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.40 vs. BCR: 5.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BCR' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 3.2  Med: 5.70 Max: 7.4
Current: 5.7
3.2
7.4
Forward Dividend Yield 0.46
BCR's Forward Dividend Yield is ranked lower than
92% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. BCR: 0.46 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.56
BCR's Yield on cost (5-Year) is ranked lower than
83% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. BCR: 0.56 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BCR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.55  Med: 0.91 Max: 1.18
Current: 0.56
0.55
1.18
3-Year Average Share Buyback Ratio 3.40
BCR's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.80 vs. BCR: 3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.7  Med: 2.40 Max: 5.3
Current: 3.4
-0.7
5.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.07
BCR's Price/Projected FCF is ranked lower than
56% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. BCR: 2.07 )
Ranked among companies with meaningful Price/Projected FCF only.
BCR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.49 Max: 2.26
Current: 2.07
0.91
2.26
Price/DCF (Earnings Based) 14.98
BCR's Price/DCF (Earnings Based) is ranked lower than
100% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. BCR: 14.98 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.36
BCR's Price/Median PS Value is ranked lower than
69% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. BCR: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
BCR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 0.84 Max: 1.27
Current: 1.36
0.37
1.27
Earnings Yield (Greenblatt) (%) 1.97
BCR's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. BCR: 1.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BCR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2  Med: 6.80 Max: 12.5
Current: 1.97
2
12.5
Forward Rate of Return (Yacktman) (%) 7.57
BCR's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.31 vs. BCR: 7.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BCR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.6  Med: 18.10 Max: 22.8
Current: 7.57
7.6
22.8

More Statistics

Revenue (TTM) (Mil) $3,470
EPS (TTM) $ 1.42
Beta0.63
Short Percentage of Float1.59%
52-Week Range $169.09 - 230.76
Shares Outstanding (Mil)73.32

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 3,660 3,859 4,006
EPS ($) 10.03 11.03 12.37
EPS w/o NRI ($) 10.03 11.03 12.37
EPS Growth Rate
(3Y to 5Y Estimate)
64.91%
» More Articles for BCR

Headlines

Articles On GuruFocus.com
5 Companies Have Hit 52-Week Highs Jun 21 2016 
5 Companies Achieve 52-Week Highs Jun 07 2016 
Dividends’ True Contribution to Total Return May Surprise You Mar 24 2016 
Medical Products Company CR Bard Has Stable Business Mar 09 2016 
The Conundrum in Health Care Investing Mar 06 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
CR Bard: Dividend Aristocrats Part 25 of 52 Nov 14 2015 
Donald Yacktman Comments on C.R. Bard Nov 05 2015 
AMG Yacktman Focused Fund 3rd Quarter Commentary Nov 05 2015 
Yacktman Focused Fund's Third-Quarter Sells and Reductions Draw Attention Oct 16 2015 

More From Other Websites
5 Companies Have Hit 5a-Week Highs Jun 21 2016
ETF’s with exposure to C.R. Bard, Inc. (New Jersey) : June 21, 2016 Jun 21 2016
Jim Cramer -- 'The Real Market's Healthier,' So Ignore the Bears Jun 13 2016
Bard Increases Quarterly Dividend Jun 08 2016
Bard Announces $500 Million Share Repurchase Authorization Jun 08 2016
Bard Increases Quarterly Dividend Jun 08 2016
Bard Announces $500 Million Share Repurchase Authorization Jun 08 2016
5 Companies Achieve 5a-Week Highs Jun 07 2016
C.R. Baird Reverses Bullish Trajectory, Should Continue to Rally Jun 06 2016
Billionaire Paul Tudor Jones Trims His Fund’s Fee Structure Amid Underperformance, Bets On These... May 24 2016
IHI’s Large Caps on May 19: Baxter Offer on Baxalta Exchange Was Oversubscribed May 23 2016
BARD C R INC /NJ/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 09 2016
6 Cash-Rich Stocks With Bullish Stock Charts May 06 2016
BARD C R INC /NJ/ Files SEC form 8-K, Other Events May 04 2016
BARD C R INC /NJ/ Financials May 04 2016
C.R. Bard, Inc. -- Moody's rates CR Bard's sr notes Baa1 May 04 2016
ETF’s with exposure to C.R. Bard, Inc. (New Jersey) : May 2, 2016 May 02 2016
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 29 2016
BARD C R INC /NJ/ Files SEC form 10-Q, Quarterly Report Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)